Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.
Boltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, McIntyre J, Currier JS, Chibowa MC, Kanyama C, Nair A, Owino-Ong'or W, Hughes M, Coffin JM, Mellors JW. Boltz VF, et al. Proc Natl Acad Sci U S A. 2011 May 31;108(22):9202-7. doi: 10.1073/pnas.1105688108. Epub 2011 May 16. Proc Natl Acad Sci U S A. 2011. PMID: 21576473 Free PMC article. Clinical Trial.
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Palmer S, Boltz VF, Chow JY, Martinson NA, McIntyre JA, Gray GE, Hopley MJ, Mayers D, Robinson P, Hall DB, Maldarelli F, Coffin JM, Mellors JW; 1100.1413 Trial Investigators. Palmer S, et al. Among authors: boltz vf. Antivir Ther. 2012;17(2):327-36. doi: 10.3851/IMP1946. Epub 2011 Nov 3. Antivir Ther. 2012. PMID: 22293443 Free PMC article. Clinical Trial.
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team. Boltz VF, et al. J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16. J Infect Dis. 2014. PMID: 24443547 Free PMC article. Clinical Trial.
Linked dual-class HIV resistance mutations are associated with treatment failure.
Boltz VF, Shao W, Bale MJ, Halvas EK, Luke B, McIntyre JA, Schooley RT, Lockman S, Currier JS, Sawe F, Hogg E, Hughes MD, Kearney MF, Coffin JM, Mellors JW. Boltz VF, et al. JCI Insight. 2019 Oct 3;4(19):e130118. doi: 10.1172/jci.insight.130118. JCI Insight. 2019. PMID: 31487271 Free PMC article. Clinical Trial.
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M Jr, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN. Ambrose Z, et al. Among authors: boltz vf. J Virol. 2007 Nov;81(22):12145-55. doi: 10.1128/JVI.01301-07. Epub 2007 Sep 12. J Virol. 2007. PMID: 17855539 Free PMC article.
Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.
Boltz VF, Ambrose Z, Kearney MF, Shao W, Kewalramani VN, Maldarelli F, Mellors JW, Coffin JM. Boltz VF, et al. J Virol. 2012 Dec;86(23):12525-30. doi: 10.1128/JVI.01963-12. Epub 2012 Aug 29. J Virol. 2012. PMID: 22933296 Free PMC article.
26 results